Genenta Science SpA ADR (NASDAQ:GNTA) saw its stock price jump 29.2% in premarket trading Tuesday after unveiling a comprehensive strategic shift into the defense and national security arena.
The Milan- and New York-based company said it will adopt a new corporate name, Saentra Forge S.p.A., as it repositions itself as an industrial consolidator targeting privately held Italian firms operating in sectors subject to Italian Golden Power legislation. Management indicated the acquisition pipeline will focus on businesses with established profitability, generally producing up to approximately c5 million in EBITDA.
As part of the pivot, Genenta has entered into a binding agreement with ATC, a specialist high-precision manufacturer of tactical rifles and weapon systems tailored for special forces. Under the agreement, Genenta will provide financing for ATC through a series of reserved capital increases, with the stated objective of moving to a controlling ownership position once specified performance milestones are met.
ATC, which holds NATO qualifications and authorization from the Italian Ministry of Defense, provided a revenue and earnings trajectory used in the announcement: projected revenues of around c4.0 million in 2026 rising to approximately c9.0 million in 2027, and forecast EBITDA in excess of c2.0 million in 2026 with an expectation of roughly doubling in 2027.
In conjunction with the strategic repositioning, the Praexidia Foundation - an organization that brings together senior figures from Italian government institutions, the defense industry, and the armed forces - has become a strategic long-term shareholder in Genenta.
While the company shifts its principal strategic emphasis toward defense-related industrial consolidation, it will not abandon its biotech activities. Instead, Genenta plans to advance its biotech platform through external partnerships rather than continuing internal development work.
The company also disclosed near-term liquidity expectations: cash, cash equivalents, and marketable securities are projected to be approximately $33 million at December 31, 2025, compared with $17.7 million at June 30, 2025.
Context and next steps
Genenta s announcement lays out a clear intent to deploy capital into defense and national security suppliers in Italy, with ATC the first identified target for financing and potential future control. The company s continued reliance on partnership models for its biotech assets was emphasized as part of the transition.